Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study

There is no fulltext present in this item.

Title:	Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study
Author(s):	Hensley, Martee L.; Enserro, Danielle; Hatcher, Helen; Ottevanger, P.B. ; Krarup-Hansen, Anders; Blay, Jean-Yves; Robison, Katina; Miller, David S.
Publication year:	2018
Source:	Journal of Clinical Oncology, vol. 36, iss. 33, (2018), pp. 3324-3330
ISSN:	0732-183X
DOI:	https://doi.org/10.1200/JCO.18.00454
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/200564
Display more details
Subject:	All institutes and research themes of the Radboud University Medical Center Radboudumc 17: Women's cancers RIHS: Radboud Institute for Health Sciences
Organization:	Medical Oncology IQ Healthcare
Journal title:	Journal of Clinical Oncology
Volume:	vol. 36
Issue:	iss. 33
Page start:	p. 3324
Page end:	p. 3330